chufangao/CTO huggingface dataset:
Clinical trial NCT04856475: Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer
Official title: An Open Label Phase II Study to Evaluate Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer
Acronym: NeraBrain
Sponsor: Jules Bordet Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Termination of collaboration with PUMA
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-11-24
Primary completion date: 2021-11-24
Completion date: 2021-11-24
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05469802: A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults
Official title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Immunogenicity of the Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Days 1 and 29 in Healthy Participants Aged 18 to 49 Years in the US
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Business reason, change in Zika virus epidemiology
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-01-02
Primary completion date: 2024-07-05
Completion date: 2024-07-05
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT05363215: A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
Official title: A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of S-217622 in Participants With Mild, Moderate, and Severe Renal Impairment and Healthy Control Participants
Sponsor: Shionogi Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-08-10
Primary completion date: 2023-04-12
Completion date: 2023-04-12
Clinical trial NCT03587363: A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
Official title: A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Mild/moderate hepatic impairment (HI) cohorts completed with no impact to erdafitinib exposure. Severe HI cohort enrollment stopped early.
Enrollment: 26.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-12-06
Primary completion date: 2020-12-22
Completion date: 2020-12-22
Clinical trial NCT03905447: The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
Official title: An Open-label, Pilot Study to Assess Safety, Tolerability, Pharmacokinetics and Effects of Inhaled PC945 in the Pre-emptive Treatment of Aspergillus Fumigatus Colonisation in Lung Transplant Recipients
Sponsor: Pulmocide Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study is being terminated early as a result of the coronavirus (COVID-19) outbreak.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-17
Primary completion date: 2020-06-01
Completion date: 2020-06-01
Clinical trial NCT03860935: Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)
Acronym: ATTRibute-CM
Sponsor: Eidos Therapeutics, a BridgeBio company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 632.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-19
Primary completion date: 2023-05-11
Completion date: 2023-05-11
Baseline population: Safety Population
Clinical trial NCT02029690: Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Official title: Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)
Acronym: TRAP
Sponsor: Polaris Group (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Enrollment: 85.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-04-23
Primary completion date: 2018-08-15
Completion date: 2020-06-30
Clinical trial NCT04938635: Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia
Official title: A Phase 2b, Double-blind, Randomised, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of VIT-2763 Multiple Doses in Adults With Transfusion-dependent Beta-thalassaemia
Sponsor: Vifor Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Strategic reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-20
Primary completion date: 2023-07-31
Completion date: 2023-07-31
Plan to share individual participant data: NO
Clinical trial NCT02777372: Stress & Premenstrual Symptoms Study
Official title: Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 84.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-01
Primary completion date: 2021-12-01
Completion date: 2021-12-01
Plan to share individual participant data: NO
Clinical trial NCT04737330: A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Official title: A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period
Acronym: ORBIT
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-29
Primary completion date: 2023-05-16
Completion date: 2023-05-16
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04285580: A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
Official title: An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-11
Primary completion date: 2022-05-14
Completion date: 2022-05-14
Baseline population: All participants who have received study intervention (ie, Bimatoprost SR administration or LUMIGAN 0.01%) with at least 1 postbaseline IOP assessment.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing, please refer to the link below
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT01113476: Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Official title: Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 176.0 (ACTUAL)
Number of arms: 1.0
Start date: 2010-04-27
Primary completion date: 2022-08-12
Completion date: 2022-08-12
Clinical trial NCT05034874: Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
Official title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 in Treatment-Seeking Individuals With Methamphetamine Use Disorder
Acronym: OUTLAST
Sponsor: InterveXion Therapeutics, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Interim analysis concluded planned study numbers combined with participant dropout rates were insufficient to meet primary endpoint.
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-09
Primary completion date: 2023-09-11
Completion date: 2023-11-07
Limitations and caveats: Early termination due to missing data leading to small numbers of participants analyzed. Participants did not submit drug tests as required.
Plan to share individual participant data: YES
IPD sharing description: Final datasets are expected to contain IXT-m200 concentrations and immunogenicity results, METH use frequencies, Treatment Effectiveness Assessment scores, and safety data over time. No individually identifiable private information will be distributed.
IPD time frame: These datasets will be available for distribution following submission to the FDA of the Clinical Study Report and publication. They will be available for 2 years after the initial publication.
IPD access criteria: These datasets and associated documentation will be made available on CD by the Sponsor to requestors under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology and not distributing to third parties; and (3) a commitment to destroying or returning the data after analyses are completed. Requests should be sent to intervexion@gmail.com.
Clinical trial NCT04461600: A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Official title: A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Acronym: TENACITY
Sponsor: Ayala Pharmaceuticals, Inc, (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-14
Primary completion date: 2022-03-23
Completion date: 2022-10-11
Plan to share individual participant data: NO
Clinical trial NCT06146374: Safety Study of SLV213 for the Treatment of COVID-19.
Official title: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Phase 1 Study of SLV213 in Healthy Volunteers
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: DMID unanimously arrived at a recommendation to terminate the study after study met cohort halting criteria.
Enrollment: 16.0 (ACTUAL)
Number of arms: 3.0
Start date: 2024-04-09
Primary completion date: 2024-07-08
Completion date: 2024-07-08
Clinical trial NCT03887624: Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
Official title: A Randomized, Parallel-group，Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety of Ethosuximide in Chinese Patients With Treatment-Resistant Depression.
Sponsor: Zhejiang University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Participates could not stand the side effects
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-21
Primary completion date: 2021-04-01
Completion date: 2021-04-01
Plan to share individual participant data: NO
Clinical trial NCT03608618: Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
Official title: A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy
Sponsor: MaxCyte, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor shift in focus
Enrollment: 14.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-08-27
Primary completion date: 2021-02-11
Completion date: 2021-08-24
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01974479: Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
Official title: Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
Sponsor: National University Health System, Singapore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Suspended for an interim review of (CAR) CD19 research strategy for the treatment of CD19 positive ALL.
Enrollment: 20.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2013-09-30
Primary completion date: 2017-02-28
Completion date: 2020-02-29
Clinical trial NCT03053440: A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
Official title: A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Acronym: ASPEN
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 201.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-25
Primary completion date: 2022-06-21
Completion date: 2022-06-21
Baseline population: Intent to Treat (ITT) Analysis Set: Includes all randomized participants assigned to an arm.
Plan to share individual participant data: YES
Clinical trial NCT05315713: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
Official title: A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was terminated due to Sponsor decision.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-10
Primary completion date: 2023-07-19
Completion date: 2023-07-19
Limitations and caveats: Early termination led to small numbers of participants for analysis.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03342300: Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Official title: Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine, a Multicentre, Open-label, Randomised Phase 2 Trial
Acronym: PDVPSTS
Sponsor: Peking University People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-06
Primary completion date: 2020-11-15
Completion date: 2020-12-30
Plan to share individual participant data: YES
Clinical trial NCT03036800: Saxenda in Obesity Services (STRIVE Study)
Official title: EFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)
Acronym: STRIVE
Sponsor: University of Leicester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 392.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-28
Primary completion date: 2021-02-28
Completion date: 2022-02-25
Limitations and caveats: Although the trial was not interrupted during COVID-19 we did issue an USM to the REC \& MHRA during the pandemic to explain that certain aspects of the trial would not be possible, however measures were put in place to ensure participant safety.
Plan to share individual participant data: NO
Clinical trial NCT02431247: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
Official title: A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects
Sponsor: Janssen Sciences Ireland UC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 725.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-06
Primary completion date: 2017-03-02
Completion date: 2020-09-30
Baseline population: The intent-to-treat (ITT) analysis set included all the participants who were randomized and received at least one dose of study treatment in the study.
Clinical trial NCT03222492: Brentuximab Vedotin for Systemic Sclerosis
Official title: Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Acronym: BRAVOS
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 6.0
Start date: 2017-09-20
Primary completion date: 2023-04-10
Completion date: 2023-04-10
Baseline population: Randomized participants in each cohort were randomized 6:2 to Brentuximab Vedotin or placebo, respectively.
Limitations and caveats: Due to slow enrollment the study was stopped before fully enrolling cohort 2 (1.2 mg/kg) and before starting cohort 3 (1.8 mg/kg).
Clinical trial NCT03059446: Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
Official title: Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Sponsor: Tobira Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was terminated early due to lack of efficacy based on the results of Part I of the AURORA study.
Enrollment: 167.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-14
Primary completion date: 2021-01-05
Completion date: 2021-01-05
Baseline population: Safety Population included all participants who received at least one dose of study drug.
Clinical trial NCT04024384: Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
Official title: Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
Acronym: DARALLO
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Promotor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-31
Primary completion date: 2024-07-31
Completion date: 2024-07-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05007678: Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease
Official title: Targeting de Novo Pyrimidine Biosynthesis by Leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19)
Acronym: DEFEAT-COVID
Sponsor: Ashford and St. Peter's Hospitals NHS Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 178.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-16
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Plan to share individual participant data: YES
IPD sharing description: We plan to share the data supporting the results in a publication.
IPD time frame: Within 2 years from publication of the main results
IPD access criteria: The anonymized data may be made available upon request following approval from the Trial Management Group and the Sponsor.
Clinical trial NCT01331018: Gene Therapy for Fanconi Anemia
Official title: Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study ended early due to end of funding.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2012-02-22
Primary completion date: 2024-02-15
Completion date: 2024-02-15